David Evans Shaw Invests in Maxwell Biosciences to Advance the New Class of

0
12


AUSTIN, Texas–(BUSINESS WIRE)–Apr 6, 2021–

Maxwell Biosciences, today announced it has secured a major investment from well-known pharmaceutical investor-entrepreneur and public service champion — David Evans Shaw. The investment will be used to advance Maxwell’s CLAROMER™ brand anti-infectives program towards clinical stage development.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210406005756/en/

David Evans Shaw (Photo: Business Wire)

Last week, peer-reviewed, open-access journal Pharmaceuticals (MDPI) published new scientific research findings co-authored by Maxwell Biosciences’ Scientific Advisory Board Member Gill Diamond, Ph.D. (University of Louisville, Department of Oral Microbiology and Infectious Diseases) and 10 ten other collaborating academic researchers, titled Potent Antiviral Activity against HSV-1 and SARS-CoV-2 by Antimicrobial Peptoids. The research findings demonstrate that several peptoids exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2.

Maxwell’s CLAROMER™ brand anti-infectives destroy a broad spectrum of viruses, as shown in preclinical studies and imaging of viral structures.

The mechanism of action of this new small molecule drug class is shown using cryo-electron microscopy imaging of treated virus structures (imaging confirmed at independent labs). The detailed images show that CLAROMER™ brand anti-infectives disrupt the viral membrane and bind the viral DNA and RNA. In preclinical studies, Maxwell’s lead product candidates have shown direct virucidal action against Hepatitis B & C (HBV, HCV), Influenza A (IAV), all tested strains of SARS-CoV-2, and Herpes Simplex Virus 1 (HSV-1). Over a decade of published academic articles illustrate selective targeting of pathogens by Maxwell’s product candidates.

In vivo safety data in human tissue and animal models (confirmed in collaboration with universities and independent labs) show that CLAROMER™ brand anti-infectives are were well tolerated in vivo at 1,000 µg/mL concentration when injected under the skin; whereas, preclinical studies indicate activity against viruses at 7 µg/mL concentration. This is a potentially optimal therapeutic window for the topical treatment of viral infections in humans, such as recurrent Herpes cold sores. Additionally, starting with a development program for topical applications may mitigate many types of systemic toxicology risk in a new, preclinical drug class.

Maxwell holds a granted composition of matter patent portfolio and the company is strongly positioned to act as a key player in the fight against viruses and other pathogens.

Shaw is Managing Partner of Black Point Group. A prominent business and social entrepreneur with extensive leadership experience in bioscience-based companies,…



Read More: David Evans Shaw Invests in Maxwell Biosciences to Advance the New Class of

Leave a reply